Cargando…
5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855642/ https://www.ncbi.nlm.nih.gov/pubmed/24324635 http://dx.doi.org/10.1371/journal.pone.0080850 |
_version_ | 1782294949690081280 |
---|---|
author | Terada, Yoshio Inoue, Keiji Matsumoto, Tatsuki Ishihara, Masayuki Hamada, Kazu Shimamura, Yoshiko Ogata, Koji Inoue, Kosuke Taniguchi, Yoshinori Horino, Taro Karashima, Takashi Tamura, Kenji Fukuhara, Hideo Fujimoto, Shimpei Tsuda, Masayuki Shuin, Taro |
author_facet | Terada, Yoshio Inoue, Keiji Matsumoto, Tatsuki Ishihara, Masayuki Hamada, Kazu Shimamura, Yoshiko Ogata, Koji Inoue, Kosuke Taniguchi, Yoshinori Horino, Taro Karashima, Takashi Tamura, Kenji Fukuhara, Hideo Fujimoto, Shimpei Tsuda, Masayuki Shuin, Taro |
author_sort | Terada, Yoshio |
collection | PubMed |
description | BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The aim of this study is to evaluate the protective role of ALA in CDDP-induced acute kidney injury (AKI). METHOD: We used CDDP-induced AKI rat model and cultured renal tubular cells (NRK-52E). We divided four groups of rats: control, CDDP only, CDDP + ALA(post);(ALA 10 mg/kg + Fe in drinking water) after CDDP, CDDP + ALA(pre & post). RESULT: CDDP increased Cr up to 6.5 mg/dl, BUN up to 230 mg/dl, and ALA significantly reduced these changes. ALA ameliorates CDDP-induced morphological renal damages, and reduced tubular apoptosis evaluated by TUNEL staining and cleaved caspase 3. Protein and mRNA levels of ATP5α, complex(COX) IV, UCP2, PGC-1α in renal tissue were significantly decreased by CDDP, and ALA ameliorates reduction of these enzymes. In contrast, Heme Oxigenase (HO)-1 level is induced by CDDP treatment, and ALA treatment further up-regulates HO-1 levels. In NRK-52E cells, the CDDP-induced reduction of protein and mRNA levels of mitochondrial enzymes was significantly recovered by ALA + Fe. CDDP-induced apoptosis were ameliorated by ALA + Fe treatment. Furthermore, we evaluated the size of transplantated bladder carcinoma to the rat skin, and ALA did not change the anti cancer effects of CDDP. CONCLUSION: These data suggested that the protective role of ALA in cisplatin-induced AKI is via protection of mitochondrial viability and prevents tubular apoptosis. Also there are no significant effects of ALA on anticancer efficiency of CDDP in rats. Thus, ALA has the potential to prevent CDDP nephrotoxicity without compromising its anticancer efficacy. |
format | Online Article Text |
id | pubmed-3855642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-38556422013-12-09 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo Terada, Yoshio Inoue, Keiji Matsumoto, Tatsuki Ishihara, Masayuki Hamada, Kazu Shimamura, Yoshiko Ogata, Koji Inoue, Kosuke Taniguchi, Yoshinori Horino, Taro Karashima, Takashi Tamura, Kenji Fukuhara, Hideo Fujimoto, Shimpei Tsuda, Masayuki Shuin, Taro PLoS One Research Article BACKGROUND/AIMS: Nephrotoxicity is a frequent and major limitation in cisplatin (CDDP)-based chemotherapy. 5-Aminolevulinic acid (ALA) is widely distributed in animal cells, and it is a precursor of tetrapyrole compounds such as heme that is fundamentally important in aerobic energy metabolism. The aim of this study is to evaluate the protective role of ALA in CDDP-induced acute kidney injury (AKI). METHOD: We used CDDP-induced AKI rat model and cultured renal tubular cells (NRK-52E). We divided four groups of rats: control, CDDP only, CDDP + ALA(post);(ALA 10 mg/kg + Fe in drinking water) after CDDP, CDDP + ALA(pre & post). RESULT: CDDP increased Cr up to 6.5 mg/dl, BUN up to 230 mg/dl, and ALA significantly reduced these changes. ALA ameliorates CDDP-induced morphological renal damages, and reduced tubular apoptosis evaluated by TUNEL staining and cleaved caspase 3. Protein and mRNA levels of ATP5α, complex(COX) IV, UCP2, PGC-1α in renal tissue were significantly decreased by CDDP, and ALA ameliorates reduction of these enzymes. In contrast, Heme Oxigenase (HO)-1 level is induced by CDDP treatment, and ALA treatment further up-regulates HO-1 levels. In NRK-52E cells, the CDDP-induced reduction of protein and mRNA levels of mitochondrial enzymes was significantly recovered by ALA + Fe. CDDP-induced apoptosis were ameliorated by ALA + Fe treatment. Furthermore, we evaluated the size of transplantated bladder carcinoma to the rat skin, and ALA did not change the anti cancer effects of CDDP. CONCLUSION: These data suggested that the protective role of ALA in cisplatin-induced AKI is via protection of mitochondrial viability and prevents tubular apoptosis. Also there are no significant effects of ALA on anticancer efficiency of CDDP in rats. Thus, ALA has the potential to prevent CDDP nephrotoxicity without compromising its anticancer efficacy. Public Library of Science 2013-12-06 /pmc/articles/PMC3855642/ /pubmed/24324635 http://dx.doi.org/10.1371/journal.pone.0080850 Text en © 2013 Terada et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Terada, Yoshio Inoue, Keiji Matsumoto, Tatsuki Ishihara, Masayuki Hamada, Kazu Shimamura, Yoshiko Ogata, Koji Inoue, Kosuke Taniguchi, Yoshinori Horino, Taro Karashima, Takashi Tamura, Kenji Fukuhara, Hideo Fujimoto, Shimpei Tsuda, Masayuki Shuin, Taro 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title | 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title_full | 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title_fullStr | 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title_full_unstemmed | 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title_short | 5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo |
title_sort | 5-aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855642/ https://www.ncbi.nlm.nih.gov/pubmed/24324635 http://dx.doi.org/10.1371/journal.pone.0080850 |
work_keys_str_mv | AT teradayoshio 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT inouekeiji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT matsumototatsuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT ishiharamasayuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT hamadakazu 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT shimamurayoshiko 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT ogatakoji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT inouekosuke 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT taniguchiyoshinori 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT horinotaro 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT karashimatakashi 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT tamurakenji 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT fukuharahideo 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT fujimotoshimpei 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT tsudamasayuki 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo AT shuintaro 5aminolevulinicacidprotectsagainstcisplatininducednephrotoxicitywithoutcompromisingtheanticancerefficiencyofcisplatininratsinvitroandinvivo |